(CercleFinance.com) – Pherecydes Pharma announced on Thursday that it had filed an application for authorization with the ANSM for a phase I clinical study in infective endocarditis caused by staphylococcus aureus.
The biotechnology company specifies that its trial should include 12 patients in four clinical centers in France, with a launch envisaged in the 3rd quarter.
Under the terms of the protocol, patients will receive two anti-S phage variants intravenously. aureus between one and three times a day, for two to four days until surgery.
The primary objective of the study is to measure the concentration of phages in the infected valve in order to identify the optimal administration schedule.
Endocarditis, a heart infection most often caused by S. aureus, leads to systematic hospitalization of patients, with very complex management.
Endocarditis requires cardiac surgeries in 15% to 45% of cases and leads to death in 20% to 30% of hospitalized patients.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
